US2019151431A1PendingUtilityA1

Immunogenic compositions for the prevention and treatment of meningococcal disease

71
Assignee: WYETH HOLDINGS LLCPriority: Oct 11, 2001Filed: Feb 7, 2019Published: May 23, 2019
Est. expiryOct 11, 2021(expired)· nominal 20-yr term from priority
Inventors:Gary W. ZlotnickLeah Diane FletcherJohn Erwin FarleyLiesel A. BernfieldRobert J. ZagurskyBenjamin J. Metcalf
A61P 37/04A61P 31/04A61P 25/00A61K 2039/6087A61K 47/646A61K 39/095Y10S530/825C12N 9/2465A61K 2039/505A61K 2039/53A61K 2039/58A61K 2039/523C12N 9/2471A61K 2039/55505A61K 47/543A61K 39/39G01N 2333/22A61K 2039/55577G01N 33/56911C07K 14/22A61K 2039/55572C12N 9/2417A61K 2039/54C07K 16/1217A61K 39/00
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.

Claims

exact text as granted — not AI-modified
1 . A method of inducing an immune response against  Neisseria meningitidis  serogroup B subfamily A in a mammal comprising administering to said mammal a composition comprising an immunologically effective amount of a composition comprising at least one isolated and purified protein having greater than 95% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 58. 
     
     
         2 . The method according to  claim 1 , wherein the composition further comprises at least one protein comprising the amino acid sequence of any of even numbered SEQ ID NOS: 176-252. 
     
     
         3 . The method according to  claim 1 , wherein the at least one isolated and purified protein is nonpathogenic. 
     
     
         4 . The method according to  claim 1 , wherein the at least one isolated and purified protein has a molecular weight of 26,000 to 30,000 daltons as measured by mass spectroscopy. 
     
     
         5 . The method according to  claim 1 , wherein the at least one isolated and purified protein has a molecular weight of 28-35 kDa as measured on a 10%-20% SDS polyacrylamide gel. 
     
     
         6 . The method according to  claim 1 , wherein said composition further comprises a pharmaceutically acceptable buffer, diluent, adjuvant or carrier. 
     
     
         7 . The method according to  claim 1 , wherein said composition further comprises a carrier. 
     
     
         8 . The method according to  claim 1 , wherein said composition further an adjuvant. 
     
     
         9 . The method according to  claim 1 , wherein said adjuvant comprises a liquid. 
     
     
         10 . The method according to  claim 1 , wherein the at least one isolated and purified protein is a recombinant protein. 
     
     
         11 . The method according to  claim 1 , wherein the at least one isolated and purified protein is isolated from native  Neisseria  species. 
     
     
         12 . The method according to  claim 1 , wherein the at least one protein is a lipoprotein. 
     
     
         13 . The method according to  claim 1 , wherein the at least one protein is non-lipidated. 
     
     
         14 . The method according to  claim 1 , wherein the composition further comprises at least one additional surface antigen of  Neisseria  species, said additional surface antigen being a non-ORF2086 protein. 
     
     
         15 . The method according to  claim 1 , wherein said composition further comprises a polysaccharide. 
     
     
         16 . The method according to  claim 1 , wherein said composition comprises an additional peptide, polypeptide or protein, wherein the at least one isolated and purified protein and the additional peptide, the additional polypeptide or the additional protein form a conjugate. 
     
     
         17 . The method according to  claim 1 , wherein the at least one isolated and purified protein comprises the amino acid sequence of SEQ ID NO: 58. 
     
     
         18 . A method of inducing an immune response against  Neisseria meningitidis  serogroup B subfamily A in a mammal comprising administering to said mammal a composition comprising an immunologically effective amount of a composition comprising at least one isolated and purified protein having greater than 95% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 60. 
     
     
         19 . The method according to  claim 18 , wherein the composition further comprises at least one protein comprising the amino acid sequence of any of even numbered SEQ ID NOS: 176-252. 
     
     
         20 . The method according to  claim 18 , wherein the at least one isolated and purified protein is nonpathogenic. 
     
     
         21 . The method according to  claim 18 , wherein the at least one isolated and purified protein has a molecular weight of 26,000 to 30,000 daltons as measured by mass spectroscopy. 
     
     
         22 . The method according to  claim 18 , wherein the at least one isolated and purified protein has a molecular weight of 28-35 kDa as measured on a 10%-20% SDS polyacrylamide gel. 
     
     
         23 . The method according to  claim 18 , wherein said composition further comprises a pharmaceutically acceptable buffer, diluent, adjuvant or carrier. 
     
     
         24 . The method according to  claim 18 , wherein said composition further comprises a carrier. 
     
     
         25 . The method according to  claim 18 , wherein said composition further an adjuvant. 
     
     
         26 . The method according to  claim 18 , wherein said adjuvant comprises a liquid. 
     
     
         27 . The method according to  claim 18 , wherein the at least one isolated and purified protein is a recombinant protein. 
     
     
         28 . The method according to  claim 18 , wherein the at least one isolated and purified protein is isolated from native  Neisseria  species. 
     
     
         29 . The method according to  claim 18 , wherein the at least one protein is a lipoprotein. 
     
     
         30 . The method according to  claim 18 , wherein the at least one protein is non-lipidated. 
     
     
         31 . The method according to  claim 18 , wherein the composition further comprises at least one additional surface antigen of  Neisseria  species, said additional surface antigen being a non-ORF2086 protein. 
     
     
         32 . The method according to  claim 18 , wherein said composition further comprises a polysaccharide. 
     
     
         33 . The method according to  claim 18 , wherein said composition comprises an additional peptide, polypeptide or protein, wherein the at least one isolated and purified protein and the additional peptide, the additional polypeptide or the additional protein form a conjugate. 
     
     
         34 . The method according to  claim 18 , wherein the at least one isolated and purified protein comprises the amino acid sequence of SEQ ID NO: 60.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.